Nieto-Coronel T, Alette O, Yacab R, Fernandez-Figueroa E, Lopez-Camarillo C, Marchat L
Int J Breast Cancer. 2024; 2024:9058033.
PMID: 39444377
PMC: 11496583.
DOI: 10.1155/2024/9058033.
Liu H, Pan D, Li P, Wang D, Xia B, Zhang R
Adv Sci (Weinh). 2023; 10(29):e2302298.
PMID: 37551034
PMC: 10582467.
DOI: 10.1002/advs.202302298.
Zarezadeh S, Sharafi A, Erabi G, Tabashiri A, Teymouri N, Mehrabi H
Recent Pat Anticancer Drug Discov. 2023; 19(4):403-502.
PMID: 37534488
DOI: 10.2174/1574892818666230803100554.
Zhang L, Liu Y, La X, Yan S, Chen Y, Liang J
Naunyn Schmiedebergs Arch Pharmacol. 2022; 396(4):705-718.
PMID: 36456746
DOI: 10.1007/s00210-022-02345-w.
Ozdemir E, Koester A, Nan X
Genes (Basel). 2022; 13(2).
PMID: 35205266
PMC: 8872464.
DOI: 10.3390/genes13020219.
Interaction of Calmodulin with the cSH2 Domain of the p85 Regulatory Subunit.
Wang G, Zhang M, Jang H, Lu S, Lin S, Chen G
Biochemistry. 2018; 57(12):1917-1928.
PMID: 29494137
PMC: 6454211.
DOI: 10.1021/acs.biochem.7b01130.
Acetylcholine-dependent upregulation of TASK-1 channels in thalamic interneurons by a smooth muscle-like signalling pathway.
Leist M, Rinne S, Datunashvili M, Aissaoui A, Pape H, Decher N
J Physiol. 2017; 595(17):5875-5893.
PMID: 28714121
PMC: 5577536.
DOI: 10.1113/JP274527.
Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer.
Wang B, Ceniccola K, Hwang S, Andrawis R, Horvath A, Freedman J
Nat Commun. 2017; 8:15921.
PMID: 28665395
PMC: 5497057.
DOI: 10.1038/ncomms15921.
Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.
Rabi T, Catapano C
Tumour Biol. 2016; 37(9):12455-12464.
PMID: 27333990
DOI: 10.1007/s13277-016-5102-2.
Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia.
Duque-Afonso J, Feng J, Scherer F, Lin C, Wong S, Wang Z
J Clin Invest. 2015; 125(9):3667-80.
PMID: 26301816
PMC: 4588292.
DOI: 10.1172/JCI81158.
Akt kinase C-terminal modifications control activation loop dephosphorylation and enhance insulin response.
Chan T, Zhang J, Tiegs B, Blumhof B, Yan L, Keny N
Biochem J. 2015; 471(1):37-51.
PMID: 26201515
PMC: 4676407.
DOI: 10.1042/BJ20150325.
PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.
Edlind M, Hsieh A
Asian J Androl. 2014; 16(3):378-86.
PMID: 24759575
PMC: 4023363.
DOI: 10.4103/1008-682X.122876.
mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions.
Matsubara S, Ding Q, Miyazaki Y, Kuwahata T, Tsukasa K, Takao S
Sci Rep. 2013; 3:3230.
PMID: 24231729
PMC: 3828572.
DOI: 10.1038/srep03230.
Genetics of melanoma.
Wangari-Talbot J, Chen S
Front Genet. 2013; 3:330.
PMID: 23372575
PMC: 3555440.
DOI: 10.3389/fgene.2012.00330.
Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy.
Jazirehi A, Wenn P, Damavand M
Am J Cancer Res. 2012; 2(2):178-91.
PMID: 22485197
PMC: 3304564.
Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.
Goodwin C, Yang Z, Yin F, Yu M, Chan R
Haematologica. 2012; 97(7):1042-7.
PMID: 22315502
PMC: 3396676.
DOI: 10.3324/haematol.2011.046896.
Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase.
Sun M, Hart J, Hillmann P, Gymnopoulos M, Vogt P
Cell Cycle. 2011; 10(21):3731-9.
PMID: 22045127
PMC: 3266008.
DOI: 10.4161/cc.10.21.17920.
Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity.
Chan T, Zhang J, Rodeck U, Pascal J, Armen R, Spring M
Proc Natl Acad Sci U S A. 2011; 108(46):E1120-7.
PMID: 22031698
PMC: 3219155.
DOI: 10.1073/pnas.1109879108.
17β-Estradiol enhances breast cancer cell motility and invasion via extra-nuclear activation of actin-binding protein ezrin.
Zheng S, Huang J, Zhou K, Zhang C, Xiang Q, Tan Z
PLoS One. 2011; 6(7):e22439.
PMID: 21818323
PMC: 3144228.
DOI: 10.1371/journal.pone.0022439.
RAS Interaction with PI3K: More Than Just Another Effector Pathway.
Castellano E, Downward J
Genes Cancer. 2011; 2(3):261-74.
PMID: 21779497
PMC: 3128635.
DOI: 10.1177/1947601911408079.